When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CBAY - CymaBay's seladelpar successful in late-stage study in bile duct disorder
CymaBay Therapeutics Inc.
CymaBay Therapeutics (NASDAQ:CBAY)announces positive results from a Phase 3 clinical trial, ENHANCE, evaluating lead drug seladelpar in patients with primary biliary cholangitis, a chronic disease in which the liver's bile ducts are slowly destroyed.
More news on: CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move,